Puma Biotechnology Inc (PBYI)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 5:03 PM
Business Wire Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to four new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, July 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on businesswire.com: https://www.businesswire.com/news/home/20260702775143/en/ Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com Original: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 5:00 PM
Business Wire Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, June 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on businesswire.com: https://www.businesswire.com/news/home/20260603750820/en/ Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com Original: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 5:15 PM
Business Wire Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma common stock to six new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, May 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on businesswire.com: https://www.businesswire.com/news/home/20260506262009/en/ Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com Original: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial ResultsApril 23, 2026 4:15 PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 7, 2026, following the release of its first quarter 2026 financial results.


The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.


About Puma Biotechnology


Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.


In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.


Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260423506633/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com
David Schull, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com




Original: Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 2, 2026 5:15 PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees.


The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, April 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).


About Puma Biotechnology


Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.


In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260402834243/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com


Original: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care ConferenceFebruary 23, 2026 4:15 PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston.


A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.


About Puma Biotechnology


Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.


In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.


Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223106044/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com


David Schull, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com


Original: Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial ResultsFebruary 12, 2026 4:07 PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year 2025 financial results.


The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.


About Puma Biotechnology


Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.


In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.


Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260212152131/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com


David Schull, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com


Original: Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)February 4, 2026 5:05 PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of Puma common stock to two new non-executive employees.


The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, February 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).


About Puma Biotechnology


Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.


In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260204668424/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com


Original: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

$PBYI Total Debt (mrq) $74.08M

PBYI under $4

PBYI under $3

PBYI under $5

PBYI new 52 week high

PBYI new 52 week high

PBYI new 52 week high

PBYI another one that rallied from a bottom in November

Awesome weekly chart

Oh man got caught up on the pump pos?? Imo

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch



Settlement Date Short Interest Percent Change
Average Daily Share Volume Days to Cover


Institutional Shares (Long) 36,969,527 - 90.42% (ex 13D/G)

10/29/2021 2,433,566 (2.75) 450,236 5.41
10/15/2021 2,502,304 (7.63) 459,252 5.45
09/30/2021 2,708,985 (5.18) 433,784 6.25
09/15/2021 2,856,832 (0.52) 280,035 10.20
08/31/2021 2,871,720 (2.43) 328,372 8.75
08/13/2021 2,943,182 (4.31) 725,213 4.06
07/30/2021 3,075,618 6.50 225,710 13.63
07/15/2021 2,887,949 7.16 379,208 7.62
06/30/2021 2,695,055 (28.42) 596,796 4.52
06/15/2021 3,765,278 (2.43) 295,913 12.72
05/28/2021 3,858,892 (6.14) 198,364 19.45
05/14/2021 4,111,495 (0.32) 289,991 14.18
04/30/2021 4,124,847 (10.31) 208,783 19.76
04/15/2021 4,598,933 (5.85) 300,473 15.31
03/31/2021 4,884,504 (0.08) 284,278 17.18
03/15/2021 4,888,562 0.17 306,537 15.95
02/26/2021 4,880,464 3.72 292,459 16.69
02/12/2021 4,705,352 (4.39) 393,276 11.96
01/29/2021 4,921,592 0.86 482,452 10.20
01/15/2021 4,879,588 (26.90) 335,116 14.56
12/31/2020 6,675,318 (14.50) 500,022 13.35
12/15/2020 7,807,144 0.81 745,137 10.48
11/30/2020 7,744,264 (4.14) 476,612 16.25
11/13/2020 8,078,496 1.03 550,301 14.68
10/30/2020 7,996,168 2.15 421,739 18.96
10/15/2020 7,827,529 7.73 507,296 15.43

Institutional Owners 330
Institutional Shares 50,649,455 - 127.38% (ex 13D/G)

09/30/2020 7,265,821 (1.57) 580,938 12.51
09/15/2020 7,381,709 (0.88) 585,635 12.60
08/31/2020 7,446,943 1.44 521,814 14.27
08/14/2020 7,341,251 3.89 1,209,694 6.07
07/31/2020 7,066,243 2.34 575,964 12.27
07/15/2020 6,904,486 1.29 874,892 7.89

Institutional Owners 327
Institutional Shares 49,805,359 - 125.26% (ex 13D/G)

06/30/2020 6,816,273 (7.63) 1,195,681 5.70
06/15/2020 7,379,135 (0.85) 896,770 8.23
05/29/2020 7,442,145 (5.55) 780,209 9.54
05/15/2020 7,879,835 0.08 1,384,689 5.69
04/30/2020 7,873,917 (6.68) 772,327 10.20
04/15/2020 8,437,711 (1.29) 982,840 8.59

Institutional Owners 305
Institutional Shares 51,940,411 - 130.63% (ex 13D/G)

03/31/2020 8,548,324 17.05 1,354,893 6.31
03/13/2020 7,303,260 3.20 1,207,635 6.05
02/28/2020 7,076,651 (3.60) 2,077,040 3.41
02/14/2020 7,340,576 (7.67) 4,110,976 1.79
01/31/2020 7,950,019 1.64 1,575,095 5.05
01/15/2020 7,822,070 12.41 1,405,368 5.57

Institutional Owners 305
Institutional Shares 44,468,763 - 111.84% (ex 13D/G)

12/31/2019 6,958,596 (1.71) 1,521,638 4.57
12/13/2019 7,079,750 3.89 2,337,233 3.03
11/29/2019 6,814,354 2.89 1,350,266 5.05
11/15/2019 6,622,759 (14.06) 1,858,307 3.56
10/31/2019 7,705,927 (5.88) 1,357,564 5.68
10/15/2019 8,187,346 0.25 1,813,875 4.51

Institutional Owners 245
Institutional Shares 44,878,890 - 112.87% (ex 13D/G)

09/30/2019 8,166,689 (8.57) 1,636,824 4.99
09/13/2019 8,931,953 0.96 1,511,734 5.91
08/30/2019 8,846,816 (0.10) 1,066,176 8.30
08/15/2019 8,855,575 20.61 2,107,135 4.20

Institutional Shares (Long) 36,969,527 - 90.42% (ex 13D/G) - change of shares - change of % MRQ

This is a large decline from the post responded to, in 2020 institutional ownership ran up to 130%.

PBYI two conferences next week
rumors than a great inverstor are buying shares
two weeks ago aprox had 2 billions shares buys
yesterday great buys at close and in ah
some eyes here

PBYI
Monsta

PBYI
neratinib fast track aproval.Friday somebody bought 1.3 billion shares at close

PBYI
some rumor about FDA aproval NERATIVID FOR METASTASIC CANCER
two studies are favorable decision.
in a few weeks or days PBYI could be balistic
parabolic mode at 220 dolars.A FEW YEARS AGO 220$ NOW 11$

PBYI you can see last trade 1.3 billions shares buy.NET BUY!!!!
somebody know someone.
Big players are here guy

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch



Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover

11/13/2020 8,078,496 1.03 550,301 14.68
10/30/2020 7,996,168 2.15 421,739 18.96
10/15/2020 7,827,529 7.73 507,296 15.43

Institutional Owners 330
Institutional Shares 50,649,455 - 127.38% (ex 13D/G)

09/30/2020 7,265,821 (1.57) 580,938 12.51
09/15/2020 7,381,709 (0.88) 585,635 12.60
08/31/2020 7,446,943 1.44 521,814 14.27
08/14/2020 7,341,251 3.89 1,209,694 6.07
07/31/2020 7,066,243 2.34 575,964 12.27
07/15/2020 6,904,486 1.29 874,892 7.89

Institutional Owners 327
Institutional Shares 49,805,359 - 125.26% (ex 13D/G)

06/30/2020 6,816,273 (7.63) 1,195,681 5.70
06/15/2020 7,379,135 (0.85) 896,770 8.23
05/29/2020 7,442,145 (5.55) 780,209 9.54
05/15/2020 7,879,835 0.08 1,384,689 5.69
04/30/2020 7,873,917 (6.68) 772,327 10.20
04/15/2020 8,437,711 (1.29) 982,840 8.59

Institutional Owners 305
Institutional Shares 51,940,411 - 130.63% (ex 13D/G)

03/31/2020 8,548,324 17.05 1,354,893 6.31
03/13/2020 7,303,260 3.20 1,207,635 6.05
02/28/2020 7,076,651 (3.60) 2,077,040 3.41
02/14/2020 7,340,576 (7.67) 4,110,976 1.79
01/31/2020 7,950,019 1.64 1,575,095 5.05
01/15/2020 7,822,070 12.41 1,405,368 5.57

Institutional Owners 305
Institutional Shares 44,468,763 - 111.84% (ex 13D/G)

12/31/2019 6,958,596 (1.71) 1,521,638 4.57
12/13/2019 7,079,750 3.89 2,337,233 3.03
11/29/2019 6,814,354 2.89 1,350,266 5.05
11/15/2019 6,622,759 (14.06) 1,858,307 3.56
10/31/2019 7,705,927 (5.88) 1,357,564 5.68
10/15/2019 8,187,346 0.25 1,813,875 4.51

Institutional Owners 245
Institutional Shares 44,878,890 - 112.87% (ex 13D/G)

09/30/2019 8,166,689 (8.57) 1,636,824 4.99
09/13/2019 8,931,953 0.96 1,511,734 5.91
08/30/2019 8,846,816 (0.10) 1,066,176 8.30
08/15/2019 8,855,575 20.61 2,107,135 4.20

Option chain 10/29 and 11/16

Blocks >= 5000


bold marks >= 10K volume

Red first 10 min after opening
Blue is >100K
Blocks 50K or greater at bottom of post.


date time last bid ask volume
11/11/20 16:01:42 8.77 8.52 8.98 5,200
11/11/20 16:00:00 8.77 8.73 8.75 55,000
11/11/20 15:54:10 8.79 8.78 8.80 15,000
11/11/20 11:36:58 8.65 8.63 8.67 7,100
11/10/20 16:00:03 8.85 8.83 8.88 6,100
11/10/20 16:00:00 8.85 8.87 8.88 47,200
11/10/20 15:30:53 8.91 8.90 8.91 5,800
11/10/20 13:51:04 8.80 8.80 8.82 15,000
11/10/20 12:08:40 8.80 8.70 8.75 5,900
11/10/20 09:30:01 8.47 8.50 8.60 5,000
11/09/20 16:00:00 8.39 8.38 8.39 42,500
11/09/20 14:35:50 8.49 8.48 8.49 6,600
11/09/20 14:09:16 8.53 8.52 8.53 8,500
11/09/20 12:06:11 8.3599 8.31 8.36 6,000
11/09/20 10:43:26 8.35 8.34 8.35 8,000
11/06/20 16:00:00 7.78 7.77 7.78 38,600
11/06/20 15:45:46 7.75 7.72 7.75 5,000
11/06/20 15:21:48 7.5601 7.56 7.57 5,000
11/06/20 12:36:32 7.49 7.50 7.51 6,000
11/06/20 09:59:38 7.8531 7.80 7.86 5,000
11/06/20 09:39:18 7.5501 7.55 7.67 20,200
11/06/20 09:36:21 7.50 7.55 7.60 6,200
11/06/20 09:30:01 7.91 7.91 8.15 11,800
11/05/20 16:00:03 8.47 8.44 8.52 6,300
11/05/20 16:00:00 8.47 8.47 8.49 33,700
11/05/20 15:21:53 8.5551 8.55 8.58 5,000
11/04/20 16:00:05 8.74 8.69 8.75 10,400
11/04/20 16:00:05 8.74 8.69 8.75 7,700
11/04/20 16:00:00 8.74 8.72 8.73 68,600
11/04/20 12:11:24 8.72 8.68 8.71 7,000
11/04/20 10:57:40 8.50 8.49 8.55 6,000
11/04/20 10:36:19 8.43 8.43 8.48 5,400
11/04/20 10:06:15 8.42 8.38 8.43 5,000
11/04/20 09:30:01 7.91 7.90 8.26 8,500
11/03/20 16:00:00 7.93 7.92 7.93 66,700
11/03/20 10:10:03 7.9801 7.98 8.02 5,000
11/03/20 09:30:00 7.75 7.62 7.73 5,600
11/02/20 16:12:43 7.8291 7.85 7.88 10,000
11/02/20 16:00:00 7.78 7.78 7.79 53,800
11/02/20 11:41:42 7.82 7.82 7.83 8,500
11/02/20 10:24:52 8.00 7.97 7.99 10,500
11/02/20 10:10:35 8.1501 8.15 8.22 10,000
10/30/20 16:00:07 8.37 8.36 8.54 6,700
10/30/20 16:00:00 8.37 8.36 8.38 128,100
10/30/20 16:00:00 8.375 8.36 8.38 127,025
10/30/20 15:50:00 8.33 8.32 8.34 5,853
10/30/20 10:08:20 8.575 8.55 8.60 15,000
10/30/20 09:45:53 8.5843 8.57 8.67 5,000
10/30/20 09:39:15 8.88 8.88 8.95 6,300
10/29/20 16:00:00 9.10 9.09 9.10 37,100
10/29/20 15:40:58 9.155 9.13 9.18 5,000
10/29/20 14:40:04 9.15 9.14 9.15 25,800
10/28/20 16:00:00 9.11 9.11 9.12 37,800
10/28/20 15:01:48 9.215 9.21 9.22 5,900
10/28/20 14:19:35 9.11 9.13 9.17 12,400
10/28/20 10:13:15 9.20 9.21 9.24 6,900
10/28/20 09:52:09 9.25 9.25 9.28 11,400
10/28/20 09:48:37 9.30 9.23 9.27 5,240
10/27/20 17:31:59 9.50 9.22 9.50 6,400
10/27/20 16:11:29 9.5566 9.23 9.50 14,800
10/27/20 16:00:00 9.50 9.51 9.52 64,300
10/27/20 15:09:40 9.50 9.50 9.53 5,400
10/27/20 12:59:31 9.66 9.63 9.65 11,900
10/27/20 12:59:31 9.66 9.63 9.65 7,400
10/27/20 10:10:35 9.51 9.46 9.50 5,500
10/27/20 09:30:00 9.24 9.23 9.45 26,500
*** Missing data
10/21/20 10:46:14 9.35 9.36 9.38 7,000
10/21/20 10:46:14 9.36 9.36 9.38 13,000
10/20/20 10:48:18 9.45 9.45 9.48 6,000
10/20/20 10:42:39 9.4832 9.42 9.46 12,604
10/20/20 09:37:14 9.74 9.71 9.77 50,000
10/20/20 09:36:55 9.735 9.70 9.77 50,000
10/19/20 16:04:54 9.745 9.66 10.29 5,300
10/19/20 16:00:00 9.745 9.74 9.75 30,600
10/19/20 11:36:30 9.9701 9.97 10.02 10,000
10/19/20 09:37:50 9.745 9.72 9.77 50,000
10/16/20 16:00:00 9.825 9.82 9.83 46,400
10/16/20 13:39:42 10.01 10.02 10.07 10,800
10/16/20 11:46:27 10.18 10.17 10.20 5,000
10/16/20 11:45:49 10.19 10.17 10.19 5,000
10/16/20 11:36:54 10.15 10.09 10.15 10,000
10/16/20 11:30:15 10.09 10.04 10.09 13,200
10/16/20 09:30:01 9.79 9.60 9.90 5,600
10/15/20 16:00:00 9.79 9.79 9.80 42,600
10/15/20 15:44:42 9.82 9.81 9.82 16,000
10/15/20 15:44:22 9.81 9.79 9.81 6,500
10/15/20 15:06:21 9.815 9.80 9.83 8,000
10/15/20 11:27:29 9.53 9.53 9.55 6,500
10/15/20 10:10:57 9.44 9.44 9.48 5,300
10/15/20 09:59:05 9.47 9.47 9.48 18,500
10/15/20 09:47:15 9.555 9.54 9.57 25,000
10/15/20 09:41:40 9.65 9.61 9.70 25,000
10/14/20 16:00:01 9.72 9.72 9.73 49,900
10/14/20 15:50:01 9.702 9.70 9.71 5,285
10/14/20 14:40:07 9.7462 9.74 9.75 5,000
10/14/20 14:26:04 9.75 9.75 9.77 7,600
10/14/20 13:33:39 9.745 9.73 9.76 75,000
10/14/20 10:23:48 10.01 10.01 10.05 5,100
10/14/20 10:18:42 9.975 9.95 10.00 6,200
10/13/20 16:14:34 9.8932 9.51 10.12 90,900
10/13/20 16:00:00 9.82 9.82 9.83 51,000
10/13/20 15:55:29 9.835 9.83 9.84 11,000
10/13/20 15:35:45 9.85 9.85 9.86 5,000
10/13/20 15:27:36 9.85 9.89 9.90 12,600
10/13/20 13:50:43 10.05 10.03 10.05 12,000
10/13/20 10:30:43 9.865 9.84 9.89 6,500
10/12/20 16:00:00 9.78 9.77 9.78 52,700
10/12/20 15:55:49 9.795 9.79 9.80 14,300
10/12/20 14:01:34 9.75 9.74 9.76 73,000
10/12/20 12:24:17 9.75 9.74 9.76 50,000
10/12/20 11:24:43 9.7673 9.76 9.80 7,000
10/12/20 10:10:55 9.7899 9.77 9.79 6,600
10/12/20 10:05:22 9.77 9.77 9.80 10,000
10/12/20 09:30:01 9.96 9.50 9.94 5,000
10/09/20 16:00:00 10.01 9.99 10.00 68,100
10/09/20 12:02:45 9.95 9.94 9.99 7,200
10/09/20 11:37:20 10.075 10.06 10.09 5,000
10/09/20 10:54:10 10.10 10.10 10.13 9,300
10/09/20 10:48:44 10.17 10.15 10.19 8,000
10/09/20 09:51:13 10.21 10.17 10.21 9,000
10/09/20 09:43:45 10.32 10.28 10.32 6,500
10/09/20 09:41:27 10.35 10.33 10.35 6,600
10/08/20 16:00:00 10.39 10.37 10.39 36,600
10/08/20 15:17:04 10.335 10.33 10.35 5,500
10/07/20 16:00:00 10.32 10.30 10.31 52,600
10/07/20 15:50:00 10.32 10.30 10.32 5,178
10/07/20 12:32:48 10.10 10.08 10.12 75,000
10/07/20 12:32:03 10.10 10.08 10.12 24,700
10/07/20 11:14:21 10.21 10.20 10.22 5,000
10/06/20 16:00:00 10.22 10.18 10.22 40,600
10/06/20 15:00:06 10.30 10.33 10.38 12,000
10/06/20 15:00:06 10.30 10.33 10.38 7,900
10/06/20 11:33:49 10.53 10.54 10.56 5,200
10/06/20 11:30:46 10.41 10.39 10.43 5,100
10/06/20 10:05:49 10.30 10.31 10.32 6,000
10/06/20 10:03:29 10.30 10.26 10.30 19,800
10/06/20 09:30:01 10.30 9.53 10.31 9,200
10/05/20 16:00:00 10.12 10.11 10.12 59,900
10/05/20 15:52:00 10.17 10.14 10.17 5,000
10/05/20 12:52:14 10.13 10.13 10.15 5,200
missing data
09/24/20 10:00:47 9.55 9.53 9.55 5,300
09/24/20 09:34:55 9.50 9.51 9.56 7,500
09/23/20 16:07:33 9.8922 9.63 10.30 7,600
09/23/20 16:00:00 9.69 9.69 9.70 61,900
09/23/20 14:22:45 9.90 9.91 9.92 7,500
09/23/20 10:09:21 10.18 10.16 10.18 5,300
09/23/20 09:30:00 10.22 10.03 10.47 5,500
09/22/20 16:00:00 10.18 10.17 10.18 164,800
09/22/20 14:58:16 10.21 10.19 10.20 18,000
09/21/20 16:00:00 9.905 9.90 9.91 186,400
09/18/20 16:32:37 10.36 9.59 10.40 9,300
09/18/20 16:00:26 10.36 10.15 10.50 44,500
09/18/20 16:00:00 10.36 10.34 10.36 691,500
09/18/20 15:54:50 10.21 10.21 10.22 11,064
09/18/20 15:50:00 10.15 10.15 10.27 6,617
09/18/20 15:10:42 10.05 10.02 10.04 8,000
09/18/20 13:26:46 9.95 9.95 9.96 10,000
09/18/20 09:30:01 10.20 9.91 10.30 45,200
09/17/20 16:00:00 10.09 10.09 10.11 161,900
09/17/20 11:55:22 10.1813 10.18 10.20 8,000
09/17/20 11:08:15 10.2734 10.26 10.28 6,200
09/16/20 16:00:21 10.03 9.77 10.25 12,600
09/16/20 16:00:00 10.03 10.01 10.02 174,000
09/16/20 11:25:32 10.08 10.08 10.09 11,200
09/15/20 16:00:49 10.1341 9.97 10.49 112,700
09/15/20 16:00:00 9.99 9.97 9.99 43,000
09/15/20 11:53:24 10.15 10.14 10.15 24,100
09/15/20 11:51:43 10.15 10.12 10.13 11,100
09/15/20 09:43:54 10.40 10.48 10.50 15,500
09/14/20 16:00:20 10.26 9.38 10.28 6,500
09/14/20 16:00:00 10.26 10.24 10.26 111,600
09/14/20 14:27:32 10.1295 10.12 10.14 9,000
09/14/20 14:10:00 10.10 10.12 10.14 6,900
09/14/20 13:48:56 10.19 10.17 10.19 10,000
09/14/20 13:47:56 10.15 10.13 10.15 11,200
09/14/20 12:37:02 10.01 10.02 10.03 6,400
09/14/20 10:06:20 9.90 9.91 9.93 6,900
09/14/20 09:30:00 9.67 9.46 9.64 6,000
09/11/20 16:00:00 9.50 9.50 9.51 29,400
09/11/20 15:55:38 9.50 9.47 9.48 5,300
09/11/20 15:30:55 9.3937 9.39 9.40 5,000
09/11/20 10:46:53 9.76 9.74 9.78 8,800
09/10/20 16:00:00 9.73 9.69 9.70 125,900
09/10/20 14:46:22 9.64 9.63 9.65 52,000
09/10/20 13:40:13 9.95 9.95 9.96 10,500
09/10/20 09:56:52 10.03 10.01 10.02 6,000
09/09/20 16:00:06 9.79 9.47 9.99 9,000
09/09/20 16:00:00 9.79 9.80 9.81 46,700
09/08/20 16:00:00 9.65 9.65 9.66 43,300
09/04/20 16:00:17 9.63 9.61 10.10 7,100
09/04/20 16:00:00 9.63 9.62 9.66 44,400
09/04/20 15:31:20 9.75 9.72 9.74 7,300
09/04/20 15:21:22 9.68 9.66 9.68 8,800
09/04/20 15:21:22 9.68 9.66 9.68 20,300
09/04/20 09:30:00 9.67 9.45 10.69 5,000
09/03/20 16:00:00 9.67 9.67 9.70 81,200
09/03/20 15:10:27 9.70 9.70 9.71 5,200
09/03/20 13:47:19 9.80 9.80 9.81 5,800
09/03/20 11:46:45 9.90 9.88 9.90 10,000
09/03/20 10:57:17 9.82 9.80 9.82 8,619
09/02/20 16:00:05 9.87 9.82 9.91 8,000
09/02/20 16:00:00 9.87 9.85 9.87 42,600
09/02/20 13:54:37 9.8199 9.80 9.82 7,700
09/02/20 10:50:23 9.955 9.94 9.97 6,500
09/02/20 10:20:03 9.92 9.88 9.92 5,000
09/02/20 10:01:34 9.80 9.80 9.81 17,100
09/02/20 09:41:59 9.83 9.80 9.83 7,300
09/01/20 16:00:06 9.80 9.50 10.75 7,900
09/01/20 16:00:00 9.80 9.76 9.78 47,600
09/01/20 14:49:22 9.52 9.52 9.54 6,100
09/01/20 14:17:35 9.49 9.47 9.50 10,000
09/01/20 14:17:33 9.50 9.47 9.51 5,000
09/01/20 11:26:30 9.70 9.71 9.73 6,300
09/01/20 10:43:00 9.80 9.80 9.81 5,000
09/01/20 10:40:18 9.89 9.89 9.91 6,400
08/31/20 16:00:34 10.291 9.80 10.56 6,500
08/31/20 16:00:09 10.29 9.80 10.56 5,200
08/31/20 16:00:01 10.29 10.29 10.32 38,900
08/31/20 16:00:01 10.29 10.29 10.32 38,073
08/31/20 14:15:34 10.425 10.41 10.44 5,000
08/31/20 13:09:57 10.38 10.37 10.38 22,800
08/31/20 11:07:12 10.34 10.32 10.34 5,100
08/28/20 17:36:22 10.06 9.65 10.16 11,500
08/28/20 16:00:00 10.06 10.04 10.05 14,200
08/28/20 10:47:42 10.16 10.13 10.14 6,000
08/28/20 10:19:04 10.10 10.08 10.10 6,700
08/28/20 10:19:04 10.10 10.08 10.10 12,200
08/27/20 16:56:06 9.9428 9.74 10.10 6,900
08/27/20 16:11:33 9.9428 9.74 10.26 6,900
08/27/20 16:00:00 10.03 10.00 10.03 27,600
08/27/20 11:59:22 9.85 9.86 9.89 15,200
08/27/20 10:07:35 10.02 10.02 10.03 13,600
08/27/20 09:53:47 10.00 9.98 10.03 5,000
08/27/20 09:35:03 9.82 9.85 9.90 7,700
08/26/20 17:08:48 9.98 9.78 10.31 6,300
08/26/20 16:00:11 9.98 9.90 10.02 8,300
08/26/20 16:00:00 9.98 9.98 9.99 30,400
08/26/20 15:05:31 10.00 10.00 10.01 12,200
08/26/20 14:55:58 10.00 10.00 10.01 5,000
08/26/20 14:38:55 10.00 10.00 10.01 5,400
08/26/20 14:11:07 10.05 10.06 10.07 5,000
08/26/20 12:59:47 10.15 10.15 10.17 14,400
08/26/20 11:51:23 10.15 10.15 10.17 10,000
08/26/20 10:40:08 10.30 10.33 10.37 7,900
08/25/20 17:09:00 10.45 10.01 10.67 28,000
08/25/20 16:00:00 10.45 10.41 10.46 26,500
08/25/20 14:34:28 10.52 10.49 10.52 5,000
08/25/20 14:34:20 10.50 10.49 10.50 6,800
08/25/20 13:28:24 10.23 10.17 10.20 7,400
08/25/20 11:38:11 10.10 10.11 10.14 5,200
08/24/20 17:31:44 10.52 10.00 10.98 11,900
08/24/20 16:50:15 10.52 10.00 10.98 12,100
08/24/20 16:00:02 10.52 10.48 10.56 6,600
08/24/20 16:00:00 10.52 10.51 10.52 41,700
08/24/20 15:13:32 10.59 10.59 10.60 15,700
08/24/20 15:13:32 10.59 10.59 10.60 6,700
08/24/20 14:53:45 10.715 10.71 10.72 5,900
08/24/20 14:53:45 10.72 10.71 10.73 18,600
08/24/20 14:23:08 10.845 10.83 10.86 22,800
08/24/20 14:23:08 10.845 10.83 10.86 5,000
08/24/20 10:29:23 10.93 10.89 10.93 29,400
08/24/20 09:30:00 10.84 10.36 11.09 11,200




Blocks >=50K
10/20/20 15:46:21 9.50 9.50 9.52 97,000
10/20/20 15:30:01 9.50 9.49 9.51 50,000
10/20/20 09:37:14 9.74 9.71 9.77 50,000
10/20/20 09:36:55 9.735 9.70 9.77 50,000
10/19/20 09:37:50 9.745 9.72 9.77 50,000
10/14/20 13:33:39 9.745 9.73 9.76 75,000
10/13/20 16:14:34 9.8932 9.51 10.12 90,900
10/13/20 16:00:00 9.82 9.82 9.83 51,000
10/12/20 16:00:00 9.78 9.77 9.78 52,700
10/12/20 14:01:34 9.75 9.74 9.76 73,000
10/12/20 12:24:17 9.75 9.74 9.76 50,000
10/09/20 16:00:00 10.01 9.99 10.00 68,100
10/07/20 16:00:00 10.32 10.30 10.31 52,600
10/07/20 12:32:48 10.10 10.08 10.12 75,000
10/05/20 16:00:00 10.12 10.11 10.12 59,900

Blocks >=25K
11/11/20 16:00:00 8.77 8.73 8.75 55,000
11/10/20 16:00:00 8.85 8.87 8.88 47,200
11/09/20 16:00:00 8.39 8.38 8.39 42,500
11/06/20 16:00:00 7.78 7.77 7.78 38,600
11/05/20 16:00:00 8.47 8.47 8.49 33,700
11/04/20 16:00:00 8.74 8.72 8.73 68,600
11/03/20 16:00:00 7.93 7.92 7.93 66,700
11/02/20 16:00:00 7.78 7.78 7.79 53,800
10/30/20 16:00:00 8.37 8.36 8.38 128,100
10/30/20 16:00:00 8.375 8.36 8.38 127,025
10/29/20 16:00:00 9.10 9.09 9.10 37,100
10/29/20 14:40:04 9.15 9.14 9.15 25,800
10/28/20 16:00:00 9.11 9.11 9.12 37,800
10/27/20 16:00:00 9.50 9.51 9.52 64,300
10/27/20 09:30:00 9.24 9.23 9.45 26,500
10/20/20 16:00:00 9.45 9.45 9.47 37,000
10/20/20 15:46:21 9.50 9.50 9.52 97,000
10/20/20 15:30:01 9.50 9.49 9.51 50,000
10/20/20 09:37:14 9.74 9.71 9.77 50,000
10/20/20 09:36:55 9.735 9.70 9.77 50,000
10/19/20 16:00:00 9.745 9.74 9.75 30,600
10/19/20 09:37:50 9.745 9.72 9.77 50,000
10/16/20 16:00:00 9.825 9.82 9.83 46,400
10/15/20 16:00:00 9.79 9.79 9.80 42,600
10/15/20 09:47:15 9.555 9.54 9.57 25,000
10/15/20 09:41:40 9.65 9.61 9.70 25,000
10/14/20 16:00:01 9.72 9.72 9.73 49,900
10/14/20 13:33:39 9.745 9.73 9.76 75,000
10/13/20 16:14:34 9.8932 9.51 10.12 90,900
10/13/20 16:00:00 9.82 9.82 9.83 51,000
10/12/20 16:00:00 9.78 9.77 9.78 52,700
10/12/20 14:01:34 9.75 9.74 9.76 73,000
10/12/20 12:24:17 9.75 9.74 9.76 50,000
10/09/20 16:00:00 10.01 9.99 10.00 68,100
10/08/20 16:00:00 10.39 10.37 10.39 36,600
10/07/20 16:00:00 10.32 10.30 10.31 52,600
10/07/20 12:32:48 10.10 10.08 10.12 75,000
10/06/20 16:00:00 10.22 10.18 10.22 40,600
10/05/20 16:00:00 10.12 10.11 10.12 59,900
09/28/20 16:00:00 10.03 10.01 10.03 45,300
09/18/20 16:00:48 10.362 0.00 0.00 185,811
09/18/20 16:00:36 10.36 0.00 0.00 185,811
09/18/20 16:00:24 10.37 0.00 0.00 185,811
09/18/20 16:00:12 10.37 0.00 0.00 185,811
09/15/20 16:00:48 10.1341 0.00 0.00 30,192
09/15/20 16:00:36 9.98 0.00 0.00 30,192
09/15/20 16:00:24 10.1341 0.00 0.00 30,192
09/15/20 16:00:12 9.99 0.00 0.00 30,192
08/25/20 17:09:00 10.45 10.01 10.67 28,000
08/07/20 16:00:48 10.27 0.00 0.00 25,243
08/07/20 16:00:36 10.25 0.00 0.00 25,243
08/07/20 16:00:24 10.27 0.00 0.00 25,243
08/07/20 16:00:12 10.25 0.00 0.00 25,243
08/05/20 12:09:48 11.4244 0.00 0.00 25,931
08/05/20 12:09:36 11.4244 0.00 0.00 25,931
08/05/20 12:09:24 11.74 0.00 0.00 25,931
08/05/20 12:09:12 11.675 0.00 0.00 25,931
08/05/20 12:07:48 11.84 0.00 0.00 32,406
08/05/20 12:07:36 11.55 0.00 0.00 32,406
08/05/20 12:07:24 11.86 0.00 0.00 32,406
08/05/20 12:07:12 11.70 0.00 0.00 32,406
08/05/20 12:06:48 11.7083 0.00 0.00 58,692
08/05/20 12:06:36 11.67 0.00 0.00 58,692
08/05/20 12:06:24 12.49 0.00 0.00 58,692
08/05/20 12:06:12 12.10 0.00 0.00 58,692
08/05/20 12:05:48 12.08 0.00 0.00 45,890
08/05/20 12:05:36 11.75 0.00 0.00 45,890
08/05/20 12:05:24 12.90 0.00 0.00 45,890
08/05/20 12:05:12 11.81 0.00 0.00 45,890
08/05/20 12:00:48 12.43 0.00 0.00 80,800
08/05/20 12:00:36 11.25 0.00 0.00 80,800
08/05/20 12:00:24 12.43 0.00 0.00 80,800
08/05/20 12:00:12 11.25 0.00 0.00 80,800
08/05/20 09:55:42 10.84 10.81 10.87 25,000
07/31/20 16:00:48 10.31 0.00 0.00 33,387
07/31/20 16:00:36 10.31 0.00 0.00 33,387
07/31/20 16:00:24 10.325 0.00 0.00 33,387
07/31/20 16:00:12 10.32 0.00 0.00 33,387
07/30/20 14:44:48 10.56 0.00 0.00 45,628
07/30/20 14:44:36 10.56 0.00 0.00 45,628
07/30/20 14:44:24 10.565 0.00 0.00 45,628
07/30/20 14:44:12 10.565 0.00 0.00 45,628
07/30/20 13:41:39 10.505 10.49 10.52 25,000
07/30/20 13:41:32 10.505 10.49 10.52 25,000
07/27/20 17:06:21 10.05 9.79 10.12 56,800
07/22/20 16:17:01 10.1252 9.98 10.40 30,900
07/21/20 16:36:27 10.5516 10.13 10.95 32,800
07/20/20 16:12:47 10.3964 9.89 10.63 41,600
07/17/20 16:15:44 10.26 10.15 10.29 170,500
07/17/20 16:11:49 10.1467 10.15 10.30 25,900
07/16/20 16:19:02 9.8248 9.71 10.09 35,900
07/15/20 16:08:52 9.9673 9.00 10.15 37,300
07/14/20 16:20:03 9.9177 9.64 10.15 32,100
07/14/20 08:14:59 10.13 9.90 10.50 85,200
07/13/20 16:06:55 10.4429 10.13 10.49 31,200
07/10/20 16:12:06 10.4127 9.90 10.63 39,800
07/09/20 16:10:12 10.2131 9.90 10.34 40,400
07/08/20 16:06:18 10.2677 10.01 10.32 31,700
07/08/20 16:00:48 10.23 0.00 0.00 30,757
07/08/20 16:00:36 10.22 0.00 0.00 30,757
07/08/20 16:00:24 10.23 0.00 0.00 30,757
07/08/20 16:00:12 10.22 0.00 0.00 30,757
07/07/20 16:27:21 10.7546 10.36 10.81 35,600
06/26/20 16:20:03 10.3429 9.75 10.74 30,100
06/26/20 16:00:01 10.32 10.27 10.30 351,100
06/22/20 17:06:30 11.85 11.30 11.98 56,400
06/19/20 16:00:48 11.30 0.00 0.00 228,022
06/19/20 16:00:36 11.25 0.00 0.00 228,022
06/19/20 16:00:24 11.30 0.00 0.00 228,022
06/19/20 16:00:12 11.25 0.00 0.00 228,022
06/19/20 15:59:48 11.25 0.00 0.00 37,791
06/19/20 15:59:36 11.14 0.00 0.00 37,791
06/19/20 15:59:24 11.30 0.00 0.00 37,791
06/19/20 15:59:12 11.16 0.00 0.00 37,791
06/18/20 11:36:48 8.92 0.00 0.00 42,495
06/18/20 11:36:36 8.90 0.00 0.00 42,495
06/18/20 11:36:24 8.92 0.00 0.00 42,495
06/18/20 11:36:12 8.912 0.00 0.00 42,495
06/17/20 16:40:01 9.00 9.00 9.30 196,300
06/17/20 16:38:49 9.00 9.00 9.30 196,300
06/12/20 16:14:14 9.4233 9.00 9.99 25,200
06/12/20 16:00:00 9.48 9.47 9.48 31,000
06/11/20 16:56:03 9.59 9.58 9.86 98,100
06/11/20 16:00:00 9.56 9.55 9.56 66,000
06/11/20 16:00:00 9.56 9.55 9.56 66,001
06/10/20 16:36:21 10.73 10.61 11.00 65,300
06/09/20 16:53:59 11.225 11.00 11.66 128,800
06/09/20 16:53:59 11.225 11.00 11.66 45,400
06/05/20 16:38:49 10.62 10.29 10.84 97,400
06/04/20 17:02:17 10.54 10.40 11.49 137,500

Blocks >= 5000


bold marks >= 10K volume

Red first 10 min after opening
Blue is >100K
Blocks 50K or greater at bottom of post.


date time last bid ask volume

10/20/20 10:48:18 9.45 9.45 9.48 6,000
10/20/20 10:42:39 9.4832 9.42 9.46 12,604
10/20/20 09:37:14 9.74 9.71 9.77 50,000
10/20/20 09:36:55 9.735 9.70 9.77 50,000
10/19/20 16:04:54 9.745 9.66 10.29 5,300
10/19/20 16:00:00 9.745 9.74 9.75 30,600
10/19/20 11:36:30 9.9701 9.97 10.02 10,000
10/19/20 09:37:50 9.745 9.72 9.77 50,000
10/16/20 16:00:00 9.825 9.82 9.83 46,400
10/16/20 13:39:42 10.01 10.02 10.07 10,800
10/16/20 11:46:27 10.18 10.17 10.20 5,000
10/16/20 11:45:49 10.19 10.17 10.19 5,000
10/16/20 11:36:54 10.15 10.09 10.15 10,000
10/16/20 11:30:15 10.09 10.04 10.09 13,200
10/16/20 09:30:01 9.79 9.60 9.90 5,600
10/15/20 16:00:00 9.79 9.79 9.80 42,600
10/15/20 15:44:42 9.82 9.81 9.82 16,000
10/15/20 15:44:22 9.81 9.79 9.81 6,500
10/15/20 15:06:21 9.815 9.80 9.83 8,000
10/15/20 11:27:29 9.53 9.53 9.55 6,500
10/15/20 10:10:57 9.44 9.44 9.48 5,300
10/15/20 09:59:05 9.47 9.47 9.48 18,500
10/15/20 09:47:15 9.555 9.54 9.57 25,000
10/15/20 09:41:40 9.65 9.61 9.70 25,000
10/14/20 16:00:01 9.72 9.72 9.73 49,900
10/14/20 15:50:01 9.702 9.70 9.71 5,285
10/14/20 14:40:07 9.7462 9.74 9.75 5,000
10/14/20 14:26:04 9.75 9.75 9.77 7,600
10/14/20 13:33:39 9.745 9.73 9.76 75,000
10/14/20 10:23:48 10.01 10.01 10.05 5,100
10/14/20 10:18:42 9.975 9.95 10.00 6,200
10/13/20 16:14:34 9.8932 9.51 10.12 90,900
10/13/20 16:00:00 9.82 9.82 9.83 51,000
10/13/20 15:55:29 9.835 9.83 9.84 11,000
10/13/20 15:35:45 9.85 9.85 9.86 5,000
10/13/20 15:27:36 9.85 9.89 9.90 12,600
10/13/20 13:50:43 10.05 10.03 10.05 12,000
10/13/20 10:30:43 9.865 9.84 9.89 6,500
10/12/20 16:00:00 9.78 9.77 9.78 52,700
10/12/20 15:55:49 9.795 9.79 9.80 14,300
10/12/20 14:01:34 9.75 9.74 9.76 73,000
10/12/20 12:24:17 9.75 9.74 9.76 50,000
10/12/20 11:24:43 9.7673 9.76 9.80 7,000
10/12/20 10:10:55 9.7899 9.77 9.79 6,600
10/12/20 10:05:22 9.77 9.77 9.80 10,000
10/12/20 09:30:01 9.96 9.50 9.94 5,000
10/09/20 16:00:00 10.01 9.99 10.00 68,100
10/09/20 12:02:45 9.95 9.94 9.99 7,200
10/09/20 11:37:20 10.075 10.06 10.09 5,000
10/09/20 10:54:10 10.10 10.10 10.13 9,300
10/09/20 10:48:44 10.17 10.15 10.19 8,000
10/09/20 09:51:13 10.21 10.17 10.21 9,000
10/09/20 09:43:45 10.32 10.28 10.32 6,500
10/09/20 09:41:27 10.35 10.33 10.35 6,600
10/08/20 16:00:00 10.39 10.37 10.39 36,600
10/08/20 15:17:04 10.335 10.33 10.35 5,500
10/07/20 16:00:00 10.32 10.30 10.31 52,600
10/07/20 15:50:00 10.32 10.30 10.32 5,178
10/07/20 12:32:48 10.10 10.08 10.12 75,000
10/07/20 12:32:03 10.10 10.08 10.12 24,700
10/07/20 11:14:21 10.21 10.20 10.22 5,000
10/06/20 16:00:00 10.22 10.18 10.22 40,600
10/06/20 15:00:06 10.30 10.33 10.38 12,000
10/06/20 15:00:06 10.30 10.33 10.38 7,900
10/06/20 11:33:49 10.53 10.54 10.56 5,200
10/06/20 11:30:46 10.41 10.39 10.43 5,100
10/06/20 10:05:49 10.30 10.31 10.32 6,000
10/06/20 10:03:29 10.30 10.26 10.30 19,800
10/06/20 09:30:01 10.30 9.53 10.31 9,200
10/05/20 16:00:00 10.12 10.11 10.12 59,900
10/05/20 15:52:00 10.17 10.14 10.17 5,000
10/05/20 12:52:14 10.13 10.13 10.15 5,200
missing data
09/24/20 10:00:47 9.55 9.53 9.55 5,300
09/24/20 09:34:55 9.50 9.51 9.56 7,500
09/23/20 16:07:33 9.8922 9.63 10.30 7,600
09/23/20 16:00:00 9.69 9.69 9.70 61,900
09/23/20 14:22:45 9.90 9.91 9.92 7,500
09/23/20 10:09:21 10.18 10.16 10.18 5,300
09/23/20 09:30:00 10.22 10.03 10.47 5,500
09/22/20 16:00:00 10.18 10.17 10.18 164,800
09/22/20 14:58:16 10.21 10.19 10.20 18,000
09/21/20 16:00:00 9.905 9.90 9.91 186,400
09/18/20 16:32:37 10.36 9.59 10.40 9,300
09/18/20 16:00:26 10.36 10.15 10.50 44,500
09/18/20 16:00:00 10.36 10.34 10.36 691,500
09/18/20 15:54:50 10.21 10.21 10.22 11,064
09/18/20 15:50:00 10.15 10.15 10.27 6,617
09/18/20 15:10:42 10.05 10.02 10.04 8,000
09/18/20 13:26:46 9.95 9.95 9.96 10,000
09/18/20 09:30:01 10.20 9.91 10.30 45,200
09/17/20 16:00:00 10.09 10.09 10.11 161,900
09/17/20 11:55:22 10.1813 10.18 10.20 8,000
09/17/20 11:08:15 10.2734 10.26 10.28 6,200
09/16/20 16:00:21 10.03 9.77 10.25 12,600
09/16/20 16:00:00 10.03 10.01 10.02 174,000
09/16/20 11:25:32 10.08 10.08 10.09 11,200
09/15/20 16:00:49 10.1341 9.97 10.49 112,700
09/15/20 16:00:00 9.99 9.97 9.99 43,000
09/15/20 11:53:24 10.15 10.14 10.15 24,100
09/15/20 11:51:43 10.15 10.12 10.13 11,100
09/15/20 09:43:54 10.40 10.48 10.50 15,500
09/14/20 16:00:20 10.26 9.38 10.28 6,500
09/14/20 16:00:00 10.26 10.24 10.26 111,600
09/14/20 14:27:32 10.1295 10.12 10.14 9,000
09/14/20 14:10:00 10.10 10.12 10.14 6,900
09/14/20 13:48:56 10.19 10.17 10.19 10,000
09/14/20 13:47:56 10.15 10.13 10.15 11,200
09/14/20 12:37:02 10.01 10.02 10.03 6,400
09/14/20 10:06:20 9.90 9.91 9.93 6,900
09/14/20 09:30:00 9.67 9.46 9.64 6,000
09/11/20 16:00:00 9.50 9.50 9.51 29,400
09/11/20 15:55:38 9.50 9.47 9.48 5,300
09/11/20 15:30:55 9.3937 9.39 9.40 5,000
09/11/20 10:46:53 9.76 9.74 9.78 8,800
09/10/20 16:00:00 9.73 9.69 9.70 125,900
09/10/20 14:46:22 9.64 9.63 9.65 52,000
09/10/20 13:40:13 9.95 9.95 9.96 10,500
09/10/20 09:56:52 10.03 10.01 10.02 6,000
09/09/20 16:00:06 9.79 9.47 9.99 9,000
09/09/20 16:00:00 9.79 9.80 9.81 46,700
09/08/20 16:00:00 9.65 9.65 9.66 43,300
09/04/20 16:00:17 9.63 9.61 10.10 7,100
09/04/20 16:00:00 9.63 9.62 9.66 44,400
09/04/20 15:31:20 9.75 9.72 9.74 7,300
09/04/20 15:21:22 9.68 9.66 9.68 8,800
09/04/20 15:21:22 9.68 9.66 9.68 20,300
09/04/20 09:30:00 9.67 9.45 10.69 5,000
09/03/20 16:00:00 9.67 9.67 9.70 81,200
09/03/20 15:10:27 9.70 9.70 9.71 5,200
09/03/20 13:47:19 9.80 9.80 9.81 5,800
09/03/20 11:46:45 9.90 9.88 9.90 10,000
09/03/20 10:57:17 9.82 9.80 9.82 8,619
09/02/20 16:00:05 9.87 9.82 9.91 8,000
09/02/20 16:00:00 9.87 9.85 9.87 42,600
09/02/20 13:54:37 9.8199 9.80 9.82 7,700
09/02/20 10:50:23 9.955 9.94 9.97 6,500
09/02/20 10:20:03 9.92 9.88 9.92 5,000
09/02/20 10:01:34 9.80 9.80 9.81 17,100
09/02/20 09:41:59 9.83 9.80 9.83 7,300
09/01/20 16:00:06 9.80 9.50 10.75 7,900
09/01/20 16:00:00 9.80 9.76 9.78 47,600
09/01/20 14:49:22 9.52 9.52 9.54 6,100
09/01/20 14:17:35 9.49 9.47 9.50 10,000
09/01/20 14:17:33 9.50 9.47 9.51 5,000
09/01/20 11:26:30 9.70 9.71 9.73 6,300
09/01/20 10:43:00 9.80 9.80 9.81 5,000
09/01/20 10:40:18 9.89 9.89 9.91 6,400
08/31/20 16:00:34 10.291 9.80 10.56 6,500
08/31/20 16:00:09 10.29 9.80 10.56 5,200
08/31/20 16:00:01 10.29 10.29 10.32 38,900
08/31/20 16:00:01 10.29 10.29 10.32 38,073
08/31/20 14:15:34 10.425 10.41 10.44 5,000
08/31/20 13:09:57 10.38 10.37 10.38 22,800
08/31/20 11:07:12 10.34 10.32 10.34 5,100
08/28/20 17:36:22 10.06 9.65 10.16 11,500
08/28/20 16:00:00 10.06 10.04 10.05 14,200
08/28/20 10:47:42 10.16 10.13 10.14 6,000
08/28/20 10:19:04 10.10 10.08 10.10 6,700
08/28/20 10:19:04 10.10 10.08 10.10 12,200
08/27/20 16:56:06 9.9428 9.74 10.10 6,900
08/27/20 16:11:33 9.9428 9.74 10.26 6,900
08/27/20 16:00:00 10.03 10.00 10.03 27,600
08/27/20 11:59:22 9.85 9.86 9.89 15,200
08/27/20 10:07:35 10.02 10.02 10.03 13,600
08/27/20 09:53:47 10.00 9.98 10.03 5,000
08/27/20 09:35:03 9.82 9.85 9.90 7,700
08/26/20 17:08:48 9.98 9.78 10.31 6,300
08/26/20 16:00:11 9.98 9.90 10.02 8,300
08/26/20 16:00:00 9.98 9.98 9.99 30,400
08/26/20 15:05:31 10.00 10.00 10.01 12,200
08/26/20 14:55:58 10.00 10.00 10.01 5,000
08/26/20 14:38:55 10.00 10.00 10.01 5,400
08/26/20 14:11:07 10.05 10.06 10.07 5,000
08/26/20 12:59:47 10.15 10.15 10.17 14,400
08/26/20 11:51:23 10.15 10.15 10.17 10,000
08/26/20 10:40:08 10.30 10.33 10.37 7,900
08/25/20 17:09:00 10.45 10.01 10.67 28,000
08/25/20 16:00:00 10.45 10.41 10.46 26,500
08/25/20 14:34:28 10.52 10.49 10.52 5,000
08/25/20 14:34:20 10.50 10.49 10.50 6,800
08/25/20 13:28:24 10.23 10.17 10.20 7,400
08/25/20 11:38:11 10.10 10.11 10.14 5,200
08/24/20 17:31:44 10.52 10.00 10.98 11,900
08/24/20 16:50:15 10.52 10.00 10.98 12,100
08/24/20 16:00:02 10.52 10.48 10.56 6,600
08/24/20 16:00:00 10.52 10.51 10.52 41,700
08/24/20 15:13:32 10.59 10.59 10.60 15,700
08/24/20 15:13:32 10.59 10.59 10.60 6,700
08/24/20 14:53:45 10.715 10.71 10.72 5,900
08/24/20 14:53:45 10.72 10.71 10.73 18,600
08/24/20 14:23:08 10.845 10.83 10.86 22,800
08/24/20 14:23:08 10.845 10.83 10.86 5,000
08/24/20 10:29:23 10.93 10.89 10.93 29,400
08/24/20 09:30:00 10.84 10.36 11.09 11,200

Blocks >= 5000

Larger EOD blocks showing up.


09/15/20 16:00:49 10.1341 9.97 10.49 112,700
09/15/20 16:00:00 9.99 9.97 9.99 43,000
09/15/20 11:53:24 10.15 10.14 10.15 24,100
09/15/20 11:51:43 10.15 10.12 10.13 11,100
09/15/20 09:43:54 10.40 10.48 10.50 15,500
09/14/20 16:00:20 10.26 9.38 10.28 6,500
09/14/20 16:00:00 10.26 10.24 10.26 111,600
09/14/20 14:27:32 10.1295 10.12 10.14 9,000
09/14/20 14:10:00 10.10 10.12 10.14 6,900
09/14/20 13:48:56 10.19 10.17 10.19 10,000
09/14/20 13:47:56 10.15 10.13 10.15 11,200
09/14/20 12:37:02 10.01 10.02 10.03 6,400
09/14/20 10:06:20 9.90 9.91 9.93 6,900
09/14/20 09:30:00 9.67 9.46 9.64 6,000
09/11/20 16:00:00 9.50 9.50 9.51 29,400
09/11/20 15:55:38 9.50 9.47 9.48 5,300
09/11/20 15:30:55 9.3937 9.39 9.40 5,000
09/11/20 10:46:53 9.76 9.74 9.78 8,800
09/10/20 16:00:00 9.73 9.69 9.70 125,900
09/10/20 14:46:22 9.64 9.63 9.65 52,000
09/10/20 13:40:13 9.95 9.95 9.96 10,500
09/10/20 09:56:52 10.03 10.01 10.02 6,000
09/09/20 16:00:06 9.79 9.47 9.99 9,000
09/09/20 16:00:00 9.79 9.80 9.81 46,700
09/08/20 16:00:00 9.65 9.65 9.66 43,300
09/04/20 16:00:17 9.63 9.61 10.10 7,100
09/04/20 16:00:00 9.63 9.62 9.66 44,400
09/04/20 15:31:20 9.75 9.72 9.74 7,300
09/04/20 15:21:22 9.68 9.66 9.68 8,800
09/04/20 15:21:22 9.68 9.66 9.68 20,300
09/04/20 09:30:00 9.67 9.45 10.69 5,000
09/03/20 16:00:00 9.67 9.67 9.70 81,200
09/03/20 15:10:27 9.70 9.70 9.71 5,200
09/03/20 13:47:19 9.80 9.80 9.81 5,800
09/03/20 11:46:45 9.90 9.88 9.90 10,000
09/03/20 10:57:17 9.82 9.80 9.82 8,619
09/02/20 16:00:05 9.87 9.82 9.91 8,000
09/02/20 16:00:00 9.87 9.85 9.87 42,600
09/02/20 13:54:37 9.8199 9.80 9.82 7,700
09/02/20 10:50:23 9.955 9.94 9.97 6,500
09/02/20 10:20:03 9.92 9.88 9.92 5,000
09/02/20 10:01:34 9.80 9.80 9.81 17,100
09/02/20 09:41:59 9.83 9.80 9.83 7,300
09/01/20 16:00:06 9.80 9.50 10.75 7,900
09/01/20 16:00:00 9.80 9.76 9.78 47,600
09/01/20 14:49:22 9.52 9.52 9.54 6,100
09/01/20 14:17:35 9.49 9.47 9.50 10,000
09/01/20 14:17:33 9.50 9.47 9.51 5,000
09/01/20 11:26:30 9.70 9.71 9.73 6,300
09/01/20 10:43:00 9.80 9.80 9.81 5,000
09/01/20 10:40:18 9.89 9.89 9.91 6,400
08/31/20 16:00:34 10.291 9.80 10.56 6,500
08/31/20 16:00:09 10.29 9.80 10.56 5,200
08/31/20 16:00:01 10.29 10.29 10.32 38,900
08/31/20 16:00:01 10.29 10.29 10.32 38,073
08/31/20 14:15:34 10.425 10.41 10.44 5,000
08/31/20 13:09:57 10.38 10.37 10.38 22,800
08/31/20 11:07:12 10.34 10.32 10.34 5,100
08/28/20 17:36:22 10.06 9.65 10.16 11,500
08/28/20 16:00:00 10.06 10.04 10.05 14,200
08/28/20 10:47:42 10.16 10.13 10.14 6,000
08/28/20 10:19:04 10.10 10.08 10.10 6,700
08/28/20 10:19:04 10.10 10.08 10.10 12,200
08/27/20 16:56:06 9.9428 9.74 10.10 6,900
08/27/20 16:11:33 9.9428 9.74 10.26 6,900
08/27/20 16:00:00 10.03 10.00 10.03 27,600
08/27/20 11:59:22 9.85 9.86 9.89 15,200
08/27/20 10:07:35 10.02 10.02 10.03 13,600
08/27/20 09:53:47 10.00 9.98 10.03 5,000
08/27/20 09:35:03 9.82 9.85 9.90 7,700
08/26/20 17:08:48 9.98 9.78 10.31 6,300
08/26/20 16:00:11 9.98 9.90 10.02 8,300
08/26/20 16:00:00 9.98 9.98 9.99 30,400
08/26/20 15:05:31 10.00 10.00 10.01 12,200
08/26/20 14:55:58 10.00 10.00 10.01 5,000
08/26/20 14:38:55 10.00 10.00 10.01 5,400
08/26/20 14:11:07 10.05 10.06 10.07 5,000
08/26/20 12:59:47 10.15 10.15 10.17 14,400
08/26/20 11:51:23 10.15 10.15 10.17 10,000
08/26/20 10:40:08 10.30 10.33 10.37 7,900
08/25/20 17:09:00 10.45 10.01 10.67 28,000
08/25/20 16:00:00 10.45 10.41 10.46 26,500
08/25/20 14:34:28 10.52 10.49 10.52 5,000
08/25/20 14:34:20 10.50 10.49 10.50 6,800
08/25/20 13:28:24 10.23 10.17 10.20 7,400
08/25/20 11:38:11 10.10 10.11 10.14 5,200
08/24/20 17:31:44 10.52 10.00 10.98 11,900
08/24/20 16:50:15 10.52 10.00 10.98 12,100
08/24/20 16:00:02 10.52 10.48 10.56 6,600
08/24/20 16:00:00 10.52 10.51 10.52 41,700
08/24/20 15:13:32 10.59 10.59 10.60 15,700
08/24/20 15:13:32 10.59 10.59 10.60 6,700
08/24/20 14:53:45 10.715 10.71 10.72 5,900
08/24/20 14:53:45 10.72 10.71 10.73 18,600
08/24/20 14:23:08 10.845 10.83 10.86 22,800
08/24/20 14:23:08 10.845 10.83 10.86 5,000
08/24/20 10:29:23 10.93 10.89 10.93 29,400
08/24/20 09:30:00 10.84 10.36 11.09 11,200

Block Trades >= 5000


08/24/20 16:50:15 10.52 10.00 10.98 12,100
08/24/20 16:00:02 10.52 10.48 10.56 6,600
08/24/20 16:00:00 10.52 10.51 10.52 41,700
08/24/20 15:13:32 10.59 10.59 10.60 15,700
08/24/20 15:13:32 10.59 10.59 10.60 6,700
08/24/20 14:53:45 10.715 10.71 10.72 5,900
08/24/20 14:53:45 10.72 10.71 10.73 18,600
08/24/20 14:23:08 10.845 10.83 10.86 22,800
08/24/20 14:23:08 10.845 10.83 10.86 5,000
08/24/20 10:29:23 10.93 10.89 10.93 29,400
08/24/20 09:30:00 10.84 10.36 11.09 11,200
08/21/20 16:00:00 10.93 10.93 10.97 39,000
08/21/20 13:23:23 10.855 10.85 10.86 12,800
08/21/20 13:23:02 10.845 10.84 10.85 5,800
08/21/20 09:30:01 10.99 10.47 11.15 12,700
08/20/20 16:00:00 11.14 11.12 11.14 31,000
08/20/20 15:48:54 11.12 11.11 11.13 5,000
08/20/20 15:38:45 11.145 11.14 11.15 5,000
08/20/20 15:38:39 11.145 11.14 11.15 5,000
08/20/20 15:38:32 11.145 11.14 11.15 5,000
08/20/20 15:03:25 11.05 11.05 11.07 5,000
08/19/20 16:00:00 10.92 10.91 10.92 41,500
08/19/20 15:55:33 10.91 10.90 10.91 5,000
08/19/20 15:48:35 10.9046 10.90 10.91 5,700
08/19/20 12:57:11 10.85 10.83 10.85 6,000
08/19/20 12:54:12 10.815 10.81 10.82 6,500
08/18/20 16:41:10 10.79 9.98 10.82 6,900
08/18/20 16:00:03 10.79 10.75 10.82 6,600
08/18/20 16:00:00 10.79 10.79 10.80 31,300
08/18/20 12:55:36 10.60 10.58 10.60 24,700
08/18/20 12:12:59 10.56 10.55 10.56 11,100
08/18/20 11:43:31 10.56 10.54 10.56 6,000
08/17/20 16:35:55 10.595 10.31 10.60 8,700
08/17/20 16:00:06 10.595 10.54 10.60 5,700
08/17/20 16:00:00 10.595 10.59 10.60 71,100
08/17/20 12:04:35 10.6075 10.59 10.61 9,100
08/17/20 10:40:19 10.32 10.30 10.31 6,900
08/14/20 16:00:00 9.83 9.82 9.84 47,900
08/14/20 14:37:04 9.715 9.71 9.72 12,900
08/14/20 13:52:50 9.60 9.59 9.60 13,800
08/14/20 12:53:04 9.495 9.49 9.50 15,000
08/14/20 11:35:02 9.61 9.61 9.62 5,900
08/14/20 10:54:22 9.6456 9.64 9.66 5,000
08/14/20 10:36:03 9.61 9.61 9.64 5,700
08/14/20 10:29:34 9.515 9.55 9.56 6,400
08/13/20 17:06:55 9.91 9.86 10.09 19,600
08/13/20 16:00:00 9.91 9.90 9.91 42,500
08/13/20 14:53:21 9.90 9.90 9.91 18,400
08/13/20 14:53:21 9.90 9.90 9.91 5,800
08/13/20 11:41:03 9.9752 9.96 9.99 5,400
08/13/20 09:30:01 9.90 9.75 9.90 5,717
08/13/20 09:30:00 9.90 9.61 10.02 5,700
08/12/20 16:00:05 9.92 9.89 9.97 5,500
08/12/20 16:00:00 9.92 9.92 9.94 74,800
08/12/20 11:21:14 9.90 9.89 9.90 5,400
08/12/20 10:48:56 9.91 9.87 9.89 5,000
08/12/20 10:31:16 9.935 9.92 9.95 8,000
08/12/20 09:30:01 10.12 10.09 10.12 6,600
08/11/20 16:00:05 10.03 9.96 10.37 8,100
08/11/20 16:00:00 10.03 10.03 10.04 53,300
08/11/20 11:34:34 10.2899 10.27 10.29 5,300
08/10/20 17:11:55 10.54 9.96 10.73 8,500
08/10/20 16:00:00 10.54 10.53 10.55 30,500
08/10/20 15:24:45 10.7004 10.69 10.71 5,000
08/10/20 15:08:18 10.715 10.71 10.72 8,600
08/10/20 14:44:44 10.60 10.59 10.60 12,100
08/10/20 14:15:40 10.4275 10.42 10.44 6,200
08/10/20 13:31:00 10.395 10.39 10.40 6,800
08/10/20 13:29:45 10.40 10.39 10.42 6,000
08/10/20 12:16:42 10.26 10.23 10.25 5,000
08/10/20 11:06:40 10.24 10.26 10.30 11,000
08/10/20 09:30:01 10.12 10.14 10.27 7,400

Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch



Settlement Date Short Interest Percent Change Average Daily Share Volume Days to Cover

07/31/2020 7,066,243 2.34 575,964 12.27
07/15/2020 6,904,486 1.29 874,892 7.89
06/30/2020 6,816,273 (7.63) 1,195,681 5.70
06/15/2020 7,379,135 (0.85) 896,770 8.23
05/29/2020 7,442,145 (5.55) 780,209 9.54
05/15/2020 7,879,835 0.08 1,384,689 5.69
04/30/2020 7,873,917 (6.68) 772,327 10.20
04/15/2020 8,437,711 (1.29) 982,840 8.59
03/31/2020 8,548,324 17.05 1,354,893 6.31
03/13/2020 7,303,260 3.20 1,207,635 6.05
02/28/2020 7,076,651 (3.60) 2,077,040 3.41
02/14/2020 7,340,576 (7.67) 4,110,976 1.79
01/31/2020 7,950,019 1.64 1,575,095 5.05
01/15/2020 7,822,070 12.41 1,405,368 5.57
12/31/2019 6,958,596 (1.71) 1,521,638 4.57
12/13/2019 7,079,750 3.89 2,337,233 3.03
11/29/2019 6,814,354 2.89 1,350,266 5.05
11/15/2019 6,622,759 (14.06) 1,858,307 3.56
10/31/2019 7,705,927 (5.88) 1,357,564 5.68
10/15/2019 8,187,346 0.25 1,813,875 4.51
09/30/2019 8,166,689 (8.57) 1,636,824 4.99
09/13/2019 8,931,953 0.96 1,511,734 5.91
08/30/2019 8,846,816 (0.10) 1,066,176 8.30
08/15/2019 8,855,575 20.61 2,107,135 4.20

Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates
Zacks
Zacks Equity Research
August 6, 2020

Puma Biotech, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $70.60 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 26.36%. This compares to year-ago revenues of $53.90 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Puma Biotech shares have added about 24.5% since the beginning of the year versus the S&P 500's gain of 3%.

What's Next for Puma Biotech?

While Puma Biotech has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Puma Biotech was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $63.29 million in revenues for the coming quarter and -$0.84 on $241.59 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.


https://finance.yahoo.com/news/puma-biotech-pbyi-tops-q2-223510130.html

Two form 4's and a strange spike to $12 on volume today.

Can anyone comment?

Pipeline

Nerlynx is targeted against the HER1, HER2, and HER4 pathways and was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.

Nerlynx Improves Cancer-Free Survival in Early Breast Cancer
The targeted agent Nerlynx demonstrated an improvement in cancer-free survival when used after Herceptin® in early-stage, HER2-positive breast cancer.

Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive. This means that the breast cancer cells have too many HER2 proteins on their surface, which stimulates the cancer cells to grow and spread.

Agents targeting the HER2 proteins and HER2 pathway have been approved for the treatment of HER2-positive breast cancers. These agents reduce the excessive biochemical signaling that stimulates cancer growth and spread in HER2-positive cancers.

Herceptin is a commonly used agent in breast cancer that is targeted against HER2 proteins. It has demonstrated improvements in outcomes among patients with HER2-positive breast cancers, including early-stage breast cancers.

Neratinib is a novel agent referred to as a tyrosine kinase inhibitor that is targeted against several biochemical pathways implicated in the growth and spread of cancer. Specifically, Nerlynx is targeted against the HER1, HER2, and HER4 pathways.

The exteNET clinical trial, included 2,840 patients from 41 countries with HE2-positive early breast cancer who had received treatment with surgery, followed by treatment including Herceptin.

Following the completion of therapy with Herceptin, one group of patients in the trial received further treatment with Nerlynx, while the other group of patients received placebo (inactive substitute) for one year.


https://news.cancerconnect.com/breast-cancer/nerlynx-treatment-of-her2-positive-breast-cancer-GbvECmUxfkCQENpZZh_yNQ

Institutions building positions

Historical Short Interest


Settlement Date
Short Interest
Percent Change
Average Daily
Share Volume
Days to Cover

05/29/2020 7,442,145 (5.55) 780,209 9.54
05/15/2020 7,879,835 0.08 1,384,689 5.69
04/30/2020 7,873,917 (6.68) 772,327 10.20
04/15/2020 8,437,711 (1.29) 982,840 8.59
03/31/2020 8,548,324 17.05 1,354,893 6.31
03/13/2020 7,303,260 3.20 1,207,635 6.05
02/28/2020 7,076,651 (3.60) 2,077,040 3.41
02/14/2020 7,340,576 (7.67) 4,110,976 1.79
01/31/2020 7,950,019 1.64 1,575,095 5.05
01/15/2020 7,822,070 12.41 1,405,368 5.57
12/31/2019 6,958,596 (1.71) 1,521,638 4.57
12/13/2019 7,079,750 3.89 2,337,233 3.03
11/29/2019 6,814,354 2.89 1,350,266 5.05
11/15/2019 6,622,759 (14.06) 1,858,307 3.56
10/31/2019 7,705,927 (5.88) 1,357,564 5.68
10/15/2019 8,187,346 0.25 1,813,875 4.51
09/30/2019 8,166,689 (8.57) 1,636,824 4.99
09/13/2019 8,931,953 0.96 1,511,734 5.91
08/30/2019 8,846,816 (0.10) 1,066,176 8.30
08/15/2019 8,855,575 20.61 2,107,135 4.20
07/31/2019 7,342,140 (2.66) 1,294,523 5.67
07/15/2019 7,542,757 10.29 992,319 7.60
06/28/2019 6,838,713 73.91 1,751,514 3.90
06/14/2019 3,932,437 (9.46) 991,47 3.97







Security PBYI / Puma Biotechnology Inc. (74587V107)
PRESIDENT AND CEO AUERBACH ALAN H
ISIN US74587V1070
Finpedia Article Puma Biotechnology
Industry Pharmaceutical Preparations
Institutional Owners 294
Institutional Shares 36,162,042 - 93.65%
Common Shares Outstanding 38,612,447 shares (as of 2019-03-31)
Institutional Value $ 893,814 USD



https://fintel.io/so/us/pbyi

* * $PBYI Video Chart 02-05-2020 * *

Link to Video - click here to watch the technical chart video

* * $PBYI Video Chart 02-04-2020 * *

Link to Video - click here to watch the technical chart video

* * $PBYI Video Chart 01-17-2020 * *

Link to Video - click here to watch the technical chart video

* * $PBYI Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

* * $PBYI Video Chart 12-10-2019 * *

Link to Video - click here to watch the technical chart video

Perfect short at $10. Up $45k

* * $PBYI Video Chart 11-08-19 * *

Link to Video - click here to watch the technical chart video

* * $PBYI Video Chart 10-08-2019 * *

Link to Video - click here to watch the technical chart video

$PBYI 3 Months Chart

$PBYI Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy (third-line disease). The FDA has informed the Company that it is not currently planning to hold an advisory committee meeting to discuss this application. The FDA confirmed that the review will have an action date of late April, 2020.

“The FDA’s acceptance of our sNDA marks another important regulatory milestone for my team,” said Alan H. Auerbach, Chief Executive Officer and President of Puma. “We look forward to working with the FDA during its review of this submission, which targets patients with HER2-positive metastatic breast cancer who have progressed on two or more prior treatments and who need additional treatment options.”

Neratinib was originally approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and is marketed in the United States as NERLYNX® tablets. In September 2018 NERLYNX was granted marketing authorization by the European Commission for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy.

The sNDA is supported by the results of the Phase III NALA trial, a randomized controlled trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in patients with third-line HER2-positive metastatic breast cancer.

About HER2-Positive Breast Cancer

Approximately 20 to 25 percent of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.

About NALA

The NALA trial is a randomized controlled Phase III trial of neratinib plus capecitabine versus Tykerb® (lapatinib) plus capecitabine in patients with third-line HER2-positive metastatic breast cancer. The trial enrolled 621 patients who were randomized (1:1) to receive either neratinib plus capecitabine or lapatinib plus capecitabine. The trial was conducted globally at sites in North America, Europe, Asia-Pacific and South America. The co-primary endpoints of the trial are centrally confirmed progression free survival (PFS) and overall survival (OS). An alpha level of 1% was allocated to the PFS and 4% allocated to OS. The study was to be considered positive if either of the co-primary endpoints was positive. Puma reached agreement with the FDA under a Special Protocol Assessment (SPA) for the design of the Phase III clinical trial and the European Medicines Agency (EMA) also provided follow-on scientific advice (SA) consistent with that of the FDA regarding the Company's Phase III trial design and endpoints used in the trial.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the FDA in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX was granted marketing authorization by the European Commission in September 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

Diarrhea: Aggressively manage diarrhea occurring despite recommended prophylaxis with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction.
Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.
ADVERSE REACTIONS: The most common adverse reactions (≥ 5%) were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increase, nail disorder, dry skin, abdominal distention, weight decreased and urinary tract infection.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. When patients require gastric acid reducing agents, use an H2-receptor antagonist or antacid. Separate NERLYNX by at least 3 hours with antacids. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists.
Strong or moderate CYP3A4 inhibitors: Avoid concomitant use.
Strong or moderate CYP3A4 inducers: Avoid concomitant use.
P-glycoprotein (P-gp) substrates: Monitor for adverse reactions of narrow therapeutic agents that are P-gp substrates when used concomitantly with NERLYNX.
USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.
Please see Full Prescribing Information for additional safety information.

The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at www.NERLYNX.com or 1-855-816-5421.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Puma Biotechnology, Inc., they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Puma Biotechnology’s future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Puma Biotechnology’s business in general, please refer to the risk factors in the section captioned “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2018 and subsequent filings with the Securities and Exchange Commission. Except as required by law, Puma Biotechnology undertakes no obligation to update or revise any forward-looking statements.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20190911005225r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20190911005225/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

David Schull or Maggie Beller, Russo Partners, +1 212 845 4235
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com

Source: Puma Biotechnology, Inc.

© Copyright Business Wire 2019

PBYI two docs are in FDA ready.Solid tumors aproval is arround the corner.Confidential information I DONT FAIL

PBYI news!!!!!!!!!!!!!
yesterday i said you guys but the NEW is near.IT GO TO 30$ in a day